On March 15, 2023, the Honorable Karen Marston of the United States District Court for the Eastern District of Pennsylvania granted final approval of a $39.8 million settlement (“Settlement”) to resolve antitrust claims against Johnson & Johnson (“J&J” or the “Company”) alleging that the company launched its “Biosimilar Readiness Plan” to block health care providers from purchasing competitor products of its infliximab biosimilar, Remicade. The Settlement previously received preliminary approval…
On February 27, 2023, the Honorable Rodney Smith of the United States District Court for the Southern District of Florida granted final approval of a $33 million settlement (“Settlement”) to resolve anti-trust claims brought against Norwegian salmon farming companies Mowi ASA, Grieg Seafood ASA, Ocean Quality AS, Salmar ASA, Cermaq, and Lerøy Seafood USA Inc. (collectively, “Defendants”). The settlement received Preliminary Approval on October 6, 2022. This action was originally…
On January 5, 2023, the Federal Trade Commission (“FTC”) unveiled a Notice of Proposed Rulemaking (“NPRM”) that would ban virtually all employment-related non-compete agreements (“NCAs”) on the ground that such agreements are an “unfair method of competition,” thereby violating Section 5 of the FTC Act. Non-compete agreements are clauses in employment contracts that prohibit employees from working for competing companies for a defined period following the employee’s departure from the contracting…
On July 5, 2022, the Honorable Colm F. Connolly of the United States District Court for the District of Delaware denied the motion to dismiss an antitrust lawsuit against AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. (“AstraZeneca”); Handa Pharmaceuticals, LLC (“Handa”); and Par Pharmaceutical, Inc. (“Par”) (collectively, “Defendants”). The lawsuit alleges that Defendants engaged in monopolistic behavior to delay the production of a generic form of AstraZeneca’s antidepressant drug Seroquel XR…
On October 6, 2022, a proposed class of indirect salmon buyers (the “Settlement Class”) obtained a class-wide settlement of $33 million to resolve antitrust claims against Norwegian salmon producers, alleging that they inflated farm-raised salmon prices in the United States. In the preliminary approval motion, counsel for the Settlement Class indicated that the settlement is “an excellent result for the class” since it would avoid lengthy litigation and the uncertainties…
PA Philadelphia | 866-540-5505
NY New York City | 866-540-5505
CA San Diego | 866-540-5505
NY New York City | 866-540-5505
CT Chester | 866-540-5505
PA Philadelphia | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
CA San Francisco | 866-540-5505
NY New York City | 866-540-5505
CA Los Angeles | 866-540-5505
FL Fort Lauderdale | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
CA Los Angeles | 866-540-5505
CT Chester | 866-540-5505
NY New York City | 866-540-5505
CA Los Angeles | 866-540-5505
CT Chester | 866-540-5505
FL Fort Lauderdale | 866-540-5505
CT Chester | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
PA Philadelphia | 866-540-5505
NY New York City | 866-540-5505
CA San Francisco | 866-540-5505
PA Philadelphia | 866-540-5505
CA San Diego | 866-540-5505
PA Philadelphia | 866-540-5505
CT Chester | 866-540-5505
NY New York City | 866-540-5505
CA San Diego | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
FL Fort Lauderdale | 866-540-5505
NJ Hoboken | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
IT Milan | 866-540-5505
PA Philadelphia | 866-540-5505
CA San Francisco | 866-540-5505
CT Chester | 866-540-5505
NY New York City | 866-540-5505
CT Chester | 866-540-5505
PA Philadelphia | 866-540-5505
CA San Diego | 866-540-5505
PA Philadelphia | 866-540-5505
CA Los Angeles | 310-203-0600